Following impressive beneficial effects obtained in BRAF-mutant melanomas with B-Raf-inhibitors and their subsequent approval, and considering the lack of therapeutic options for resistant/relapsing GB, there has been a growing interest in using this therapeutic approach has been rising in the last few years. Here, BRAF is linked to melanoma.